Do you want to read an article? Please log in or register.
TROPION-Lung01: Datopotamab deruxtecan shows a clinically meaningful trend toward improved OS versus docetaxel in patients with NSCLC
Lung, Respiratory and Thoracic Cancer
WCLC 2024
Related content
Lung, Respiratory and Thoracic Cancer
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
J Clin Oncol
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J, TROPION-Lung01 Trial Investigators
doi: 10.1200/JCO-24-01544
WCLC 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Quantitative Continuous Scoring of TROP2 Normalized Membrane Ratio Predicts Clinical Outcomes in Patients With NSCLC
ESMO 2024
Further Publications
LBA 2. POD1UM-303/InterAACT 2: Adding retifanlimab to chemotherapy improves PFS and shows a trend toward improved OS in SCAC
ESMO 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Dato-DXd benefits patients with advanced non-squamous NSCLC with or without brain metastases
ELCC 2024
Lung, Respiratory and Thoracic Cancer
EMPOWER-Lung 3: Frontline cemiplimab combination improves PRO versus chemotherapy in patients with advanced NSCLC
ASCO 2024
Genitourinary Cancer
ARASENS: Adding darolutamide to ADT plus docetaxel delays progression to castrate-resistant disease and improves OS in patients with mHSPC
COMMENTED
Breast Cancer
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B, TROPION-Breast01 Investigators
doi: 10.1200/JCO.24.00920
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
Lung Cancer
Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S
doi: 10.1016/j.lungcan.2024.107921
Lung, Respiratory and Thoracic Cancer
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)
Lung Cancer
Johnson M, Younan D, Kent ST, Mesa-Frias M, Alan Brookhart M, Balasubramanian A, Spira A
doi: 10.1016/j.lungcan.2024.107960